In general, weight reduction from GLP1-RA therapy in those without diabetes (but with overweight or obesity) tends to be greater (6.1–7.4%) than in those with diabetes (4% to 6.2%) [14]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.